Patent 11912746 was granted and assigned to 2seventy bio, Inc. on February, 2024 by the United States Patent and Trademark Office.
The present disclosure provides improved genome editing compositions and methods for editing a PD-1 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.